Clinical Trial

HMNC Brain Health's new oral ketamine shows promise by minimizing side effects, but an unmet endpoint raises questions. Is this the key to at-home TRD care?

As OKYO Pharma woos investors with a promising eye drug, it carries the hopes of patients with debilitating pain. A look at the science, stakes, and systems.

With €33M in new funding, Cyllene Therapeutics is advancing a novel gene therapy using HSV-1 vectors. Could this be the one-shot cure for millions?

Vivos Inc. wins FDA approval for a human trial of RadioGel®, a targeted therapy that could offer new hope for patients with non-resectable thyroid cancer.

With a new ADC expert as CMO, Corbus Pharmaceuticals is advancing its dual pipeline. This move signals a critical phase for its cancer drug and obesity therapy.

IceCure's ProSense™ is reshaping oncology in Brazil. A US FDA approval provided a critical tailwind, validating a less invasive future for cancer care.

A South Korean biotech's diabetes drug finds new purpose in fighting FSHD, backed by a foundation's innovative funding model that could reshape rare disease R&D.

Australian biotech Immuron hires a top dealmaker to land a partner for its novel C. diff therapy. The goal: secure funding and unlock a potential $400M market.

UK biotech Ananda Pharma advances its MRX1 drug to Phase 2 trials, targeting a debilitating chemotherapy side effect with no current effective treatment.

Immunomic Therapeutics begins human trials for ITI-9001, an saRNA vaccine aiming to rewrite the immune response to Japanese cedar pollen allergy.

Cerezen, a non-invasive device shown to reverse cognitive decline, has EU approval but remains in FDA limbo, raising questions about US patient access.

NKGen Biotech signals a strategic pivot to Asia, leveraging its novel NK cell therapy, troculeucel, to tap into China's new, accelerated biotech pathways.

Revolution Medicines' zoldonrasib delivers high response rates in trials for RAS G12D pancreatic cancer, offering a beacon of hope against a lethal disease.

Xeltis's bioabsorbable aXess graft hits a major US trial milestone, signaling a strategic shift in renal care away from failing synthetics to living tissue.

Molecular Partners and Orano Med begin human trials for a novel radiopharmaceutical, hoping to unlock a new front against small cell lung cancer.

A new study for CRENESSITY could revolutionize care for infants with classic congenital adrenal hyperplasia, shifting the treatment paradigm and solidifying market leadership.

For women with resistant ovarian cancer, options are few. A new drug, NTB-928, uses a dual-key design to unlock the immune system against tumors.

Intensity Therapeutics shows promising results for its cancer-killing drug, but can it navigate the biotech funding crunch and land a vital pharma partner?

Kowa's pemafibrate gets FDA Breakthrough status for a rare liver disease. We dissect what this means for patients, the science, and the company's global strategy.

Millions suffer from chronic cough with no cure. A Boston biotech is testing a novel aerosol that targets the root cause, not just symptoms. Could it be the first disease-modifying treatment?